乳腺癌中MTA1，ER的表达及其相关性研究

目的 观察MTA1,ER在乳腺癌中的表达,探讨两者与乳腺癌侵袭能力的相关性.方法 应用原位核酸分子杂交和免疫组织化学分别检测正常乳腺组织、癌前病变组织及乳腺癌组织中MTA1,ER的表达;并以Spearman等级相关分析它们的相关性.结果 在正常乳腺组织、癌前病变组织、乳腺癌组织中,原位杂交对MTA1,ER的阳性检出率高于免疫组化,原位杂交检测中MTA1 mRNA的表达率分别为12.2%,33.3%,81.1%;免疫组化检测中MTA1的表达率分别为11.1%,31.1%,72.2%;原位杂交检测中ER mRNA的表达率分别为83.3%.61.1%,37.8%,免疫组化检测中ER的表达率分别为70.9%,56.7%和35.6%.MTA1在ER阴性组中的阳性表达率为86.2%,高于阳性组中的46.9%.结论 原位杂交和免疫组化联合检测增加MTA1,ER基因的检出率;随疾病的进展和肿瘤分化程度的降低,MTA1表达逐渐增强,ER表达逐渐减弱,甚至丧失.MTA1与ER表达呈负相关(r=-0.466,P＜0.01).提示MTA1,ER可作为乳腺癌预后及治疗重要的分子标记物.

Research on the expression and the relationship of MTA1 and ER in breast cancer

Objective:To observe the expression of MTA1 and ER in breast cancer, the correlation of the two factors and with the invasive capability of breast cancer. Methods :The expression of MTA1 and ER in normal breast, precancerous lesions and breast cancer tissues was detected by using nucleic acid hybridization in situ(ISH) and immunocytochemistry(IHC) methods, and their correlation was analyzed by Spearman method.Results:The expression of MTA1 and ER was higher in ISH than in IHC. The mRNA expression of MTA1 in normal breast tissue, precancerous lesions and breast cancer tissne was 12.2%，33.3%, and 81.1% respectively, and the expression by IHC was 11.1%, 31.1% and 72.2% respectively. The mRNA expression of ER in normal breast tissue, precancerous lesions and breast cancer tissue was 83.3%，61.1% and 37.8%,respectively, and the expression by IHC was70.9%，56.7% and 35.6% respectively.The positive expression of MTA1 was higher in ER-negative patients than that in ER-positive ones(86.2﹪vs.46.9﹪).Conclusions:Combined ISH and IHC detection can improve the detection rate of MTA1 and ER. With advancement of the disease and lowering of tumor differentiation,the expression of MTA1 gradually increases,while expression of ER decreases and even disappears.The expression of MTA1 is negative in relation to that of ER (the coefficient is -0.466).MTA1and ER could be important molecular markers for the prognosis and therapy of breast cancer.